MedTrace Logo

Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds

NCT01285050 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2016-11-29

Study results available
· View outcomes & findings →

Summary

The chief purpose of this research is to evaluate interferon alpha sensitivity and cell type specific levels of interferon receptor and interferon stimulated genes and proteins in HIV/ HCV (hepatitis C virus) coinfected persons before and after administration of HIV medications (antiretroviral therapy).

Conditions

  • HIV Infection
  • Hepatitis C

Interventions

DRUG

Antiretroviral therapy (ART)

Peginterferon alfa-2b administered once as part of a pharmacokinetic study before and after anti-HIV medications. Peginterferon is used to produce a measurement but the intervention is the HIV medications which are specified as raltegravir, emtricitabline, and tenofovir disoproxil fumerate.

DRUG

raltegravir

raltegravir is an HIV medication given 400 mg twice daily by mouth

DRUG

Emtricitabine and tenofovir disoproxil fumarate

Emtricitabine and tenofovir disoproxil fumarate are HIV medications, combination pill, once per day by mouth

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2015-04-30
Completion
2015-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01285050 on ClinicalTrials.gov